EyeGene describes itself as a bio venture whose main business is R&D in medicine and pharmacy, but its revenue structure looks closer to wholesale.
According to a Green Economy report, 99.7% of revenue as of year-end 2025 came from wholesale of products of its largest shareholder, BMI Korea, with no own-manufactured product sales and no own new-drug approvals in 25 years.
BMI Korea became the largest shareholder after investing KRW 15.0 billion in December 2023 and raised its stake from 21.48% to 23.18% through a rights offering. The pipeline has four strands.
The first is the recombinant botulinum toxin EG-rBTX100, for which BMI Korea applied to the Ministry of Food and Drug Safety for export approval on August 12, 2026.
The second is non-exclusive out-licensing of the toxin manufacturing technology, which the company plans to pursue with global firms in the United States, Europe and China. The third is the tetravalent meningococcal vaccine EG-MCV4, which received domestic Phase 2/3 approval.
The fourth is the mRNA vaccine BMI2012, which received Phase 1 IND approval on August 12, 2026. In recombinant toxins, a Chinese developer, Claruvis Biotech, received FDA IND clearance for its liquid recombinant toxin YY003 in September 2024, so competition already exists.
In September 2026, EyeGene was selected as a co-research institution in two Korean ARPA-H-style projects under the Ministry of Health and Welfare, with total government funding of KRW 26.0 billion over five years.
Because each pipeline's monetization depends on approval and clinical timelines, near-term revenue contribution is limited.